Methylation testing for the detection of recurrent cervical intraepithelial neoplasia
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34678 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Stèfanie Dick und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council.
Abstract (Originalsprache)
Women treated for CIN2 /3 remain at increased risk of recurrent CIN and cervical cancer, and therefore posttreatment surveillance is recommended. This post hoc analysis evaluates the potential of methylation markers ASCL1 / LHX8 and FAM19A4 / miR124 ‐2 for posttreatment detection of recurrent CIN2 /3. Cervical scrapes taken at 6 and 12 months posttreatment of 364 women treated for CIN2 /3 were tested for methylation of ASCL1 / LHX8 and FAM19A4 / miR124 ‐2 using quantitative multiplex methylation‐specific PCR . Performance of the methylation tests were calculated and compared with the performance of HPV and/or cytology. Methylation levels of recurrent CIN were compared between women with a persistent HPV infection, and women with an incident HPV infection or without HPV infection. Recurrent CIN2 /3 was detected in 42 women (11.5%), including 28 women with CIN2 and 14 with CIN3 . ASCL1 / LHX8 tested positive in 13/14 (92.9%) of recurrent CIN3 and 13/27 (48.1%) of recurrent CIN2 . FAM19A4 / miR124 ‐2 tested positive in 14/14 (100%) of recurrent CIN3 and 10/27 (37.0%) of recurrent CIN2 . Combined HPV and/or methylation testing showed similar positivity rates as HPV and/or cytology. The CIN2 /3 risk at 12 months posttreatment was 30.8% after a positive ASCL1 / LHX8 result at 6 months posttreatment. Methylation levels of CIN2 /3 in women with a persistent HPV infection were significantly higher compared with women with an incident or no HPV infection. In conclusion, posttreatment monitoring by methylation analysis of ASCL1 / LHX8 and FAM19A4 / miR124 ‐2 showed a good performance for the detection of recurrent CIN . DNA methylation testing can help to identify women with recurrent CIN that require re‐treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Department of Gynecological Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Epidemiology and Data Science, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Stèfanie Dick, Renske D M Steenbergen
Förderung
- European Research Council
Zitieren
APA
Dick, S., Heideman, D. A. M., Mom, C. H., Meijer, C. J. L. M., Berkhof, J., Steenbergen, R. D. M., & Bleeker, M. C. G. (2023). Methylation testing for the detection of recurrent cervical intraepithelial neoplasia. International Journal of Cancer. https://doi.org/10.1002/ijc.34678
Vancouver
Dick S, Heideman DAM, Mom CH, Meijer CJLM, Berkhof J, Steenbergen RDM, et al. Methylation testing for the detection of recurrent cervical intraepithelial neoplasia. International Journal of Cancer. 2023. doi:10.1002/ijc.34678
BibTeX
@article{Dick2023,
author = {Dick, Stèfanie and Heideman, Daniëlle A M and Mom, Constantijne H and Meijer, Chris J L M and Berkhof, Johannes and Steenbergen, Renske D M and Bleeker, Maaike C G},
title = {Methylation testing for the detection of recurrent cervical intraepithelial neoplasia},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34678}
}
EUVIMED